Literature DB >> 29910702

Mutational Screening in Tyrosine-Kinase Domain of erbB1 And erbB2 Genes.

Juan Manuel Fernández Alonso1.   

Abstract

Entities:  

Year:  2005        PMID： 29910702      PMCID： PMC6001051     

Source DB:  PubMed          Journal:  EJIFCC        ISSN： 1650-3414


× No keyword cloud information.
  6 in total

Review 1.  Recent developments related to the EGFR as a target for cancer chemotherapy.

Authors:  Georgina Speake; Brian Holloway; Gerard Costello
Journal:  Curr Opin Pharmacol       Date:  2005-08       Impact factor: 5.547

Review 2.  EGFR and cancer prognosis.

Authors:  R I Nicholson; J M Gee; M E Harper
Journal:  Eur J Cancer       Date:  2001-09       Impact factor: 9.162

3.  Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.

Authors:  Sean Tracy; Toru Mukohara; Mark Hansen; Matthew Meyerson; Bruce E Johnson; Pasi A Jänne
Journal:  Cancer Res       Date:  2004-10-15       Impact factor: 12.701

4.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

Review 5.  Growth factor receptors as targets for lung cancer therapy.

Authors:  Dao M Nguyen; David S Schrump
Journal:  Semin Thorac Cardiovasc Surg       Date:  2004

6.  Variability in organ-specific EGFR mutational spectra in tumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors.

Authors:  F Weber; K Fukino; T Sawada; N Williams; K Sweet; R M Brena; C Plass; T Caldes; G L Mutter; M A Villalona-Calero; C Eng
Journal:  Br J Cancer       Date:  2005-05-23       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.